With early data and a possible advantage, Amgen enters the obesity drug race
Amgen's candidate works similarly to Lilly and Novo drugs, but with a twist that could induce greater, longer-lasting weight loss.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
FDA approves first fecal microbiome drug, setting stage for others
On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues
Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny
Opinion
Why the U.S. needs a public benefit biopharma industry
Biopharma is failing Americans, both medically and economically. We need a public benefit biopharma industry.
Read The Story
Video
Watch: An interview with the FDA’s top cancer regulator
Rich Pazdur, the director of the FDA Oncology Center of Excellence, addressed rapid approvals, diversity in clinical trials, and more.
Read The Story
All Coverage
advertisement
